These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 20606092)

  • 1. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.
    Fouladi M; Park JR; Stewart CF; Gilbertson RJ; Schaiquevich P; Sun J; Reid JM; Ames MM; Speights R; Ingle AM; Zwiebel J; Blaney SM; Adamson PC
    J Clin Oncol; 2010 Aug; 28(22):3623-9. PubMed ID: 20606092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
    Hummel TR; Wagner L; Ahern C; Fouladi M; Reid JM; McGovern RM; Ames MM; Gilbertson RJ; Horton T; Ingle AM; Weigel B; Blaney SM
    Pediatr Blood Cancer; 2013 Sep; 60(9):1452-7. PubMed ID: 23554030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916).
    Muscal JA; Thompson PA; Horton TM; Ingle AM; Ahern CH; McGovern RM; Reid JM; Ames MM; Espinoza-Delgado I; Weigel BJ; Blaney SM
    Pediatr Blood Cancer; 2013 Mar; 60(3):390-5. PubMed ID: 22887890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors.
    Fakih MG; Fetterly G; Egorin MJ; Muindi JR; Espinoza-Delgado I; Zwiebel JA; Litwin A; Holleran JL; Wang K; Diasio RB
    Clin Cancer Res; 2010 Jul; 16(14):3786-94. PubMed ID: 20463088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.
    Ramalingam SS; Parise RA; Ramanathan RK; Lagattuta TF; Musguire LA; Stoller RG; Potter DM; Argiris AE; Zwiebel JA; Egorin MJ; Belani CP
    Clin Cancer Res; 2007 Jun; 13(12):3605-10. PubMed ID: 17510206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.
    Schelman WR; Traynor AM; Holen KD; Kolesar JM; Attia S; Hoang T; Eickhoff J; Jiang Z; Alberti D; Marnocha R; Reid JM; Ames MM; McGovern RM; Espinoza-Delgado I; Wright JJ; Wilding G; Bailey HH
    Invest New Drugs; 2013 Dec; 31(6):1539-46. PubMed ID: 24114121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.
    Pinto N; DuBois SG; Marachelian A; Diede SJ; Taraseviciute A; Glade Bender JL; Tsao-Wei D; Groshen SG; Reid JM; Haas-Kogan DA; Reynolds CP; Kang MH; Irwin MS; Macy ME; Villablanca JG; Matthay KK; Park JR
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27023. PubMed ID: 29603591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors.
    Dickson MA; Rathkopf DE; Carvajal RD; Grant S; Roberts JD; Reid JM; Ames MM; McGovern RM; Lefkowitz RA; Gonen M; Cane LM; Dials HJ; Schwartz GK
    Invest New Drugs; 2011 Oct; 29(5):1004-12. PubMed ID: 20461440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.
    Lee EQ; Puduvalli VK; Reid JM; Kuhn JG; Lamborn KR; Cloughesy TF; Chang SM; Drappatz J; Yung WK; Gilbert MR; Robins HI; Lieberman FS; Lassman AB; McGovern RM; Xu J; Desideri S; Ye X; Ames MM; Espinoza-Delgado I; Prados MD; Wen PY
    Clin Cancer Res; 2012 Nov; 18(21):6032-9. PubMed ID: 22923449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.
    ; Fouladi M; Furman WL; Chin T; Freeman BB; Dudkin L; Stewart CF; Krailo MD; Speights R; Ingle AM; Houghton PJ; Wright J; Adamson PC; Blaney SM
    J Clin Oncol; 2006 Aug; 24(22):3678-85. PubMed ID: 16877737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).
    Schafer ES; Rau RE; Berg S; Liu X; Minard CG; D'Adamo D; Scott R; Reyderman L; Martinez G; Devarajan S; Reid JM; Fox E; Weigel BJ; Blaney SM
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27066. PubMed ID: 29719113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.
    Park H; Garrido-Laguna I; Naing A; Fu S; Falchook GS; Piha-Paul SA; Wheler JJ; Hong DS; Tsimberidou AM; Subbiah V; Zinner RG; Kaseb AO; Patel S; Fanale MA; Velez-Bravo VM; Meric-Bernstam F; Kurzrock R; Janku F
    Oncotarget; 2016 Oct; 7(41):67521-67531. PubMed ID: 27589687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors.
    Deming DA; Ninan J; Bailey HH; Kolesar JM; Eickhoff J; Reid JM; Ames MM; McGovern RM; Alberti D; Marnocha R; Espinoza-Delgado I; Wright J; Wilding G; Schelman WR
    Invest New Drugs; 2014 Apr; 32(2):323-9. PubMed ID: 24114123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.
    Stathis A; Hotte SJ; Chen EX; Hirte HW; Oza AM; Moretto P; Webster S; Laughlin A; Stayner LA; McGill S; Wang L; Zhang WJ; Espinoza-Delgado I; Holleran JL; Egorin MJ; Siu LL
    Clin Cancer Res; 2011 Mar; 17(6):1582-90. PubMed ID: 21278245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report.
    Fouladi M; Perentesis JP; Wagner LM; Vinks AA; Reid JM; Ahern C; Thomas G; Mercer CA; Krueger DA; Houghton PJ; Doyle LA; Chen H; Weigel B; Blaney SM
    Clin Cancer Res; 2015 Apr; 21(7):1558-65. PubMed ID: 25467181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies.
    Kim KP; Park SJ; Kim JE; Hong YS; Lee JL; Bae KS; Cha H; Kwon SK; Ro S; Cho J; Kim TW
    Invest New Drugs; 2015 Oct; 33(5):1048-57. PubMed ID: 26076682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial.
    Luu T; Frankel P; Beumer JH; Lim D; Cristea M; Appleman LJ; Lenz HJ; Gandara DR; Kiesel BF; Piekarz RL; Newman EM
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1201-1208. PubMed ID: 31522242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors.
    Morita S; Oizumi S; Minami H; Kitagawa K; Komatsu Y; Fujiwara Y; Inada M; Yuki S; Kiyota N; Mitsuma A; Sawaki M; Tanii H; Kimura J; Ando Y
    Invest New Drugs; 2012 Oct; 30(5):1950-7. PubMed ID: 21964801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.
    Fox E; Maris JM; Widemann BC; Goodspeed W; Goodwin A; Kromplewski M; Fouts ME; Medina D; Cohn SL; Krivoshik A; Hagey AE; Adamson PC; Balis FM
    Clin Cancer Res; 2008 Feb; 14(4):1111-5. PubMed ID: 18281544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.
    Widemann BC; Kim A; Fox E; Baruchel S; Adamson PC; Ingle AM; Glade Bender J; Burke M; Weigel B; Stempak D; Balis FM; Blaney SM
    Clin Cancer Res; 2012 Nov; 18(21):6011-22. PubMed ID: 22962440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.